Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy. Issue 3 (September 2019)
- Record Type:
- Journal Article
- Title:
- Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy. Issue 3 (September 2019)
- Main Title:
- Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy
- Authors:
- Maayah, Zaid H.
McGinn, Erica
Al Batran, Rami
Gopal, Keshav
Ussher, John R.
El-Kadi, Ayman O. S. - Abstract:
- Abstract : Abstract: A plethora of studies have demonstrated that cardiomyopathy represents a serious source of morbidity and mortality in patients with diabetes. Yet, the underlying mechanisms of diabetic cardiomyopathy are still poorly understood. Of interest, cytochrome P450 2J (CYP2J) and soluble epoxide hydrolase (sEH) are known to control the maintenance of cardiovascular health through the regulation of cardioprotective epoxyeicosatrienoic acids (EETs) and its less active products, dihydroxyeicosatrienoic acids (DHETs). Therefore, we examined the role of the aforementioned pathway in the development of diabetic cardiomyopathy. Our diabetic model initiated cardiomyopathy as indexed by the increase in the expression of hypertrophic markers such as NPPA . Furthermore, diabetic cardiomyopathy was associated with a low level of cardiac EETs and an increase of the DHETs/EETs ratio both in vivo and in cardiac cells. The modulation in EETs and DHETs was attributed to the increase of sEH and the decrease of CYP2J. Interestingly, the reduction of sEH attenuates cardiotoxicity mediated by high glucose in cardiac cells. Mechanistically, the beneficial effect of sEH reduction might be due to the decrease of phosphorylated ERK1/2 and p38. Overall, the present work provides evidence that diabetes initiates cardiomyopathy through the increase in sEH, the reduction of CYP2J, and the decrease of cardioprotective EETs. Abstract : Supplemental Digital Content is Available in the Text.
- Is Part Of:
- Journal of cardiovascular pharmacology. Volume 74:Issue 3(2019)
- Journal:
- Journal of cardiovascular pharmacology
- Issue:
- Volume 74:Issue 3(2019)
- Issue Display:
- Volume 74, Issue 3 (2019)
- Year:
- 2019
- Volume:
- 74
- Issue:
- 3
- Issue Sort Value:
- 2019-0074-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-09
- Subjects:
- diabetic cardiomyopathy -- cytochrome P450 -- soluble epoxide hydrolase
Cardiovascular Diseases -- drug therapy -- Periodicals
Cardiovascular System -- drug effects -- Periodicals
Cardiovascular pharmacology -- Periodicals
Cardiovascular agents -- Periodicals
Cardiovascular agents
Cardiovascular pharmacology
Periodicals
615.7105 - Journal URLs:
- http://journals.lww.com/cardiovascularpharm/pages/default.aspx ↗
http://www.cardiovascularpharm.com ↗
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00005344-000000000-00000 ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/FJC.0000000000000707 ↗
- Languages:
- English
- ISSNs:
- 0160-2446
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4954.868000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12024.xml